Login to Your Account

Arsanis Adds $20M in Series B for Staph Drug

By Nuala Moran
Staff Writer

Friday, September 6, 2013
LONDON – Arsanis Inc. has raised $20 million in Series B funding that will enable the Austro-American company to take its lead monoclonal antibody product, ASN-100, through Phase I/IIa development in the treatment of severe, hospital-acquired Staphylococcus aureus infections.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription